Literature DB >> 21170282

The concept of depression as a dysfunction of the immune system.

Brian E Leonard1.   

Abstract

Chronic stress, by initiating changes in the hypothalamic-pituitary-adrenal axis and the immune system, acts as a trigger for anxiety and depression. Both experimental and clinical evidence shows that a rise in the concentrations of proinflammatory cytokines and glucocorticoids, as occurs in chronically stressful situations and in depression, contribute to the behavioural changes associated with depression.A defect in serotonergic function is associated with hypercortisolaemia and the increase in proinflammatory cytokines that accompany depression. Glucocorticoids and proinflammatory cytokines enhance the conversion of tryptophan to kynurenine. In addition to the resulting decrease in the synthesis of brain serotonin, this leads to the formation of neurotoxins such as the glutamate agonist quinolinic acid and contributes to the increase in apoptosis of astrocytes, oligodendroglia and neurons.The importance of the inflammation hypothesis of depression lies in raising the possibility that psychotropic drugs that have a central anti-inflammatory action might provide a new generation of antidepressants.

Entities:  

Year:  2010        PMID: 21170282      PMCID: PMC3002174          DOI: 10.2174/157339510791823835

Source DB:  PubMed          Journal:  Curr Immunol Rev        ISSN: 1573-3955


  71 in total

1.  Cytokine production and treatment response in major depressive disorder.

Authors:  S Lanquillon; J C Krieg; U Bening-Abu-Shach; H Vedder
Journal:  Neuropsychopharmacology       Date:  2000-04       Impact factor: 7.853

Review 2.  Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders.

Authors:  Hymie Anisman; Zul Merali; Shawn Hayley
Journal:  Prog Neurobiol       Date:  2008-02-13       Impact factor: 11.685

3.  Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.

Authors:  Charles L Raison; Andrey S Borisov; Matthias Majer; Daniel F Drake; Giuseppe Pagnoni; Bobbi J Woolwine; Gerald J Vogt; Breanne Massung; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

4.  Central mediation of the effects of interleukin-1 on social exploration and body weight in mice.

Authors:  R M Bluthé; R Dantzer; K W Kelley
Journal:  Psychoneuroendocrinology       Date:  1997-01       Impact factor: 4.905

Review 5.  Regulation of 5-HT receptors by corticosteroids: where do we stand?

Authors:  F Chaouloff
Journal:  Fundam Clin Pharmacol       Date:  1995       Impact factor: 2.748

6.  Kynurenine pathway in major depression: evidence of impaired neuroprotection.

Authors:  Aye-Mu Myint; Yong Ku Kim; Robert Verkerk; Simon Scharpé; Harry Steinbusch; Brian Leonard
Journal:  J Affect Disord       Date:  2006-09-06       Impact factor: 4.839

7.  Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier.

Authors:  Tomitsune Kitagami; Kiyofumi Yamada; Hideki Miura; Ryo Hashimoto; Toshitaka Nabeshima; Tatsurou Ohta
Journal:  Brain Res       Date:  2003-07-18       Impact factor: 3.252

8.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

Authors:  N Müller; M J Schwarz; S Dehning; A Douhe; A Cerovecki; B Goldstein-Müller; I Spellmann; G Hetzel; K Maino; N Kleindienst; H-J Möller; V Arolt; M Riedel
Journal:  Mol Psychiatry       Date:  2006-02-21       Impact factor: 15.992

Review 9.  Gliogenesis and glial pathology in depression.

Authors:  G Rajkowska; J J Miguel-Hidalgo
Journal:  CNS Neurol Disord Drug Targets       Date:  2007-06       Impact factor: 4.388

Review 10.  Treatment of inflammatory diseases by selective eicosanoid inhibition: a double-edged sword?

Authors:  Saul Yedgar; Miron Krimsky; Yuval Cohen; Roderick J Flower
Journal:  Trends Pharmacol Sci       Date:  2007-08-10       Impact factor: 14.819

View more
  79 in total

1.  Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder.

Authors:  David Mischoulon; Jonathan E Alpert; Erland Arning; Teodoro Bottiglieri; Maurizio Fava; George I Papakostas
Journal:  J Clin Psychiatry       Date:  2012-05-15       Impact factor: 4.384

2.  Systemic Inhibition of Soluble Tumor Necrosis Factor with XPro1595 Exacerbates a Post-Spinal Cord Injury Depressive Phenotype in Female Rats.

Authors:  Kaitlin Farrell; John D Houle
Journal:  J Neurotrauma       Date:  2019-07-10       Impact factor: 5.269

3.  Repeatedly administered antidepressant drugs modulate humoral and cellular immune response in mice through action on macrophages.

Authors:  Katarzyna Nazimek; Michael Kozlowski; Pawel Bryniarski; Spencer Strobel; Agata Bryk; Michal Myszka; Anna Tyszka; Piotr Kuszmiersz; Jaroslaw Nowakowski; Iwona Filipczak-Bryniarska
Journal:  Exp Biol Med (Maywood)       Date:  2016-04-05

Review 4.  Current neurological observations and complications of dengue virus infection.

Authors:  Marylou V Solbrig; Guey-Chuen Perng
Journal:  Curr Neurol Neurosci Rep       Date:  2015-06       Impact factor: 5.081

Review 5.  New advances on glial activation in health and disease.

Authors:  Kim Mai Lee; Andrew G MacLean
Journal:  World J Virol       Date:  2015-05-12

Review 6.  From stress to inflammation and major depressive disorder: a social signal transduction theory of depression.

Authors:  George M Slavich; Michael R Irwin
Journal:  Psychol Bull       Date:  2014-01-13       Impact factor: 17.737

7.  Early life environment and developmental immunotoxicity in inflammatory dysfunction and disease.

Authors:  Cynthia A Leifer; Rodney R Dietert
Journal:  Toxicol Environ Chem       Date:  2011       Impact factor: 1.437

Review 8.  Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression.

Authors:  Renaud Massart; Raymond Mongeau; Laurence Lanfumey
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-09-05       Impact factor: 6.237

9.  The effect of TNF-alpha blockers on psychometric measures in ankylosing spondylitis patients: a preliminary observation.

Authors:  Ozden Arısoy; Cemal Bes; Cigdem Cifci; Mustafa Sercan; Mehmet Soy
Journal:  Rheumatol Int       Date:  2013-01-20       Impact factor: 2.631

Review 10.  Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways.

Authors:  F B Del Guerra; J L I Fonseca; V M Figueiredo; E B Ziff; E Castelon Konkiewitz
Journal:  J Neurovirol       Date:  2013-07-19       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.